ChemicalBook > Product Catalog >Pharmaceutical intermediates >Bulk Drug Intermediates >Dabrafenib Mesylate

Dabrafenib Mesylate

Dabrafenib Mesylate Suppliers list
Company Name: AFINE CHEMICALS LIMITED
Tel: +86-0571-85134551
Email: info@afinechem.com
Products Intro: Product Name:DABRAFENIB MESYLATE
CAS:1195768-06-9
Purity:98%+ Package:Standard or custom package Remarks:excellent quality and reliable supplier
Company Name: Beijing Mesochem Technology Co.,Ltd
Tel: +8613651027935
Email: rachel@mesochem.com
Products Intro: Product Name:Dabrafenib Mesylate
CAS:1195768-06-9
Purity:0.99 Package:100kg;10kg;1kg;100g;10g;5g;1g
Company Name: Zison Pharmaceutical (Shandong) Co., Ltd.
Tel: +86-0086-531-88259693 +86-18660188356
Email: tracy.li@zisonpharm.com
Products Intro: Product Name:Dabrafenib Mesylate
CAS:1195768-06-9
Purity:99.9 Package:10g
Company Name: Zibo Hangyu Biotechnology Development Co., Ltd
Tel: +86-0533-2185556 +8617865335152
Email: Mandy@hangyubiotech.com
Products Intro: Product Name:Dabrafenib Mesylate(GSK-2118436B)
CAS:1195768-06-9
Purity:0.99 Package:1kg;80USD|10kg;800USD
Company Name: Henan Fengda Chemical Co., Ltd
Tel: +86-371-86557731 +86-13613820652
Email: info@fdachem.com
Products Intro: Product Name:Dabrafenib Mesylate
CAS:1195768-06-9
Purity:98% Package:1KG;6USD|1000KG;0.2USD

Dabrafenib Mesylate manufacturers

  • Dabrafenib mesylate
  • Dabrafenib mesylate pictures
  • $0.00 / 1kg
  • 2024-07-02
  • CAS:1195768-06-9
  • Min. Order: 1kg
  • Purity: >99.5% by HPLC
  • Supply Ability: 100kg/month
  • Dabrafenib Mesylate
  • Dabrafenib Mesylate pictures
  • $0.00 / 10g
  • 2024-07-02
  • CAS:1195768-06-9
  • Min. Order: 10g
  • Purity: 99.9
  • Supply Ability: 20kgs

Related articles

Dabrafenib Mesylate Basic information
Description
Product Name:Dabrafenib Mesylate
Synonyms:Dabrafenib Mesylate(GSK-2118436B);GSK 2118436 Mesylate;GSK 2118436B;GSK2118436 Mesylate;GSK-2118436 Mesylate;Dabrafenib Mesylate (API);GSK 2118436 methanesulfonate salt;N-[3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl]-2-fluorophenyl]-2,6-difluoro-benzenesulfonamide methanesulfonate
CAS:1195768-06-9
MF:C24H24F3N5O5S3
MW:615.66
EINECS:689-167-4
Product Categories:Raf B protein kinase inhibitor;API
Mol File:1195768-06-9.mol
Dabrafenib Mesylate Structure
Dabrafenib Mesylate Chemical Properties
Melting point >234oC (dec.)
storage temp. Hygroscopic, -20°C Freezer, Under inert atmosphere
solubility DMSO (Slightly, Heated), Methanol (Slightly)
form White solid.
color White to Off-White
Stability:Hygroscopic
InChIKeyYKGMKSIHIVVYKY-UHFFFAOYSA-N
SMILESS(O)(=O)(=O)C.FC1C(=CC=CC=1C1N=C(C(C)(C)C)SC=1C1C=CN=C(N)N=1)NS(C1C(=CC=CC=1F)F)(=O)=O
Safety Information
HS Code 2935909099
MSDS Information
Dabrafenib Mesylate Usage And Synthesis
Description

Dabrafenib Mesylate(1195768-06-9) is a salt form of Dabrafenib. Dabrafenib is an inhibitor of certain mutated forms of BRAF kinase, several of which may be associated with stimulating tumour growth (e.g. the BRAF V600E mutation), and Dabrafenib is also an inhibitor of BRAF V600-mutation positive cancer cell growth, both in vitro and in vivo.

DescriptionDabrafenib mesylate, sold by GlaxoSmithKline under the trade name Tafinlar, was approved by the U.S. FDA in May 2013 for the treatment of metastatic BRAF-mutant melanoma. Dabrafenib reversibly inhibits the BRAF(V600E) mutant kinase as a selective ATP-competitive inhibitor which results in tumor regression.
UsesDabrafenib is an inhibitor of mutated BRAF kinase and has clinical activity with a manageable safety profile in clinical trials of phase 1 and 2 in patients with BRAF(V600)-mutated metastatic melanoma.
DefinitionChEBI: A methanesulfonate (mesylate) salt prepared from equimolar amounts of dabrafenib and methanesulfonic acid. Used for treatment of metastatic melanoma.
SynthesisCommercially available fluoroaniline 40 was first converted to sulfonamide 42 in 91% yield by treatment with 2,5-difluorobenzenesulfonyl chloride (41) in the presence of pyridine. Next, deprotonation of 2-chloro-4-methylpyrimidine (43) with lithium bis(trimethylsilyl)amide (LHMDS) followed by addition to ester 42 afforded chloropyrimidine 44 in 72% yield. Bromination followed by thiazole formation through the use of 2,2-dimethylpropanethioamide gave the penultimate target 45 in 80% over two steps. Chloropyrimidine 45 was subjected to SNAr conditions with ammonium hydroxide to furnish the aminopyrimidine in 88% yield, and this was followed by exposure to methanesulfonic acid to afford dabrafenib mesylate (VI) in 85% yield.

Synthesis_1195768-06-9

targetRaf
storageStore at -20°C
references[1]namba h, nakashima m, hayashi t, hayashida n, maeda s, rogounovitch ti, ohtsuru a, saenko va, kanematsu t, yamashita s. clinical implication of hot spot braf mutation, v599e, in papillary thyroid cancers. j. clin. endocrinol. metab. 2003; 88 (9): 4393–7.
[2]tan yh, liu y, eu kw, ang pw, li wq, salto-tellez m, iacopetta b, soong r. detection of braf v600e mutation by pyrosequencing. pathology 2008; 40 (3): 295–8.
[3]davies h, bignell gr, cox c, et al. mutations of the braf gene in human cancer. nature. 2002; 417: 949-954.
[4]ma xh, piao sf, dey s, mcafee q, karakousis g, villanueva j, hart ls, levi s, hu j, zhang g, lazova r, klump v, pawelek jm, xu x, xu w, schuchter lm, davies ma, herlyn m, winkler j, koumenis c, amaravadi rk. targeting er stress-induced autophagy overcomes braf inhibitor resistance in melanoma. j clin invest. 2014; 124(3): 1406-17.
Tag:Dabrafenib Mesylate(1195768-06-9) Related Product Information
Methanesulfonic acid Phentolamine mesilate Osimertinib mesylate Selumetinib Cabozantinib Dabrafenib Trametinib Crizotinib AZD-9291 Vandetanib